NILO Therapeutics, Inc.

Nilo Therapeutics, based in the US, is engaged in developing innovative immunomodulation therapies designed to restore immune balance in autoimmune and inflammatory diseases, focusing on master regulatory brain-body circuits. Nilo Therapeutics specializes in the development of therapies that target neural circuits to address autoimmune and inflammatory diseases. Founded in 2024 and headquartered in New York, US, the company raised USD 101. 00 mn in Series A funding in October 2025, co-led by The Column Group, Data Collective, and Lux Capital, with participation from Gates Family Foundation and Alexandria Venture Investments.

The company has completed one deal to date. Nilo Therapeutics is focused on pioneering innovative immunomodulation therapies that leverage neural circuits to restore immune homeostasis in various autoimmune and inflammatory diseases. The company's core offerings center around targeting master regulatory brain-body circuits that play a critical role in managing systemic inflammation. This differentiated approach aims to address a broad range of conditions with significant unmet medical needs, thereby providing potential relief to patients suffering from these diseases.

Nilo's solutions are intended for healthcare providers, including hospitals and specialized clinics, who serve patients across multiple geographical markets including North America and Europe, where the demand for advanced treatments is particularly pronounced. Nilo Therapeutics operates a revenue model primarily based on partnerships and collaborations with healthcare providers and research institutions, which facilitates the integration of their therapies into clinical settings. Transactions occur through direct agreements with hospitals and clinics, enabling them to access Nilo's products for their patient populations. Given the nature of their offerings, these transactions involve structured pricing plans that reflect the complexity and anticipated outcomes of the therapies provided, though specific pricing structures for these products are not disclosed.

In October 2025, Nilo Therapeutics raised USD 101. 00 mn in Series A funding to build laboratories in New York, grow its research and development team, and advance preclinical programs. The company plans to design and launch new products that target systemic inflammation and aims to expand into new markets, particularly in Europe and North America, by the end of 2026.